Fluoxetine (Prozac) versus ...
Fluoxetine (Prozac) appears to be the weakest of the SSRIs. Due to
its very long half-life and relatively weak potency as a serotonin
inhibitor fluoxetine has less prominent discontinuation symptoms than many other
Fluoxetine unique features led to that Prozac is the only SSRI approved
by the FDA for use in children 8 years of age and older.
Fluoxetine (Prozac) vs. Citalopram (Celexa)
Major depressive disorder
Citalopram is as effective as fluoxetine
in the treatment of major depression. In the study citalopram
showed an earlier onset of recovery than fluoxetine 12.
In the study patients treated with fluoxetine
displayed a greater reduction in introjected anger, whereas those
treated with citalopram displayed a greater reduction in depressive
feelings. Citalopram may be useful in depressed patients with bulimia,
whereas fluoxetine is more specific for those with introjected anger
and bulimia 13.
Sexual side effects
Citalopram delays ejaculation more significantly than fluoxetine 27.
Fluoxetine (Prozac) vs. Paroxetine (Paxil)
Major depressive disorder
Paroxetine and fluoxetine have comparable efficacy
in the treatment of depression. However, paroxetine has a significantly
higher response rate than fluoxetine. Paroxetine appears to produce
earlier antidepressant effect, improvement in agitation and anxiety symptoms 22, 23.
Constipation, dyspepsia, tremor, sweating and abnormal ejaculation are more common with paroxetine, whereas
nausea and nervousness are more frequent with fluoxetine. Weight loss
is more common with fluoxetine 23.
Discontinuation of paroxetine is more often associated with somatic and psychological symptoms than
discontinuation of fluoxetine. Patients treated with fluoxetine appear
to be protected by its longer half-life 1.
Fluoxetine (Prozac) vs. Sertraline (Zoloft)
Sertraline and fluoxetine have comparable
antidepressant efficacy in the treatment of Major depression. However,
sertraline has advantages over fluoxetine in those patients with severe
depression and low anxiety in the melancholia 17, 18.
Both medications have significant
efficacy in the treatment of moderate to severe OCD. However, patients
treated with sertraline have a greater likelihood of remission as
well as an earlier improvement 20.
Sertraline is considered to be better
tolerated than fluoxetine 19.
Sertraline has advantages over fluoxetine
on parameters such as sleep and weight disturbance in severely depressed
patients, and sleep disturbance, weight, cognitive disturbance and
retardation in melancholic patients 18.
Fluoxetine is associated with a higher incidence of agitation,
anxiety and insomnia than sertraline 19.
Fluoxetine has fewer discontinuation-emergent
events than sertraline 21.
Sertraline has significantly lower potential for drug interactions than fluoxetine.
Fluoxetine (Prozac) vs. Venlafaxine (Effexor)
Major depressive disorder
Venlafaxine appears to be superior
to fluoxetine and produces higher rate of remission in the treatment
for depression 24. Venlafaxine's
superior remission rates in the more severely anxious patients and
its ability to improve psychic anxiety compared with fluoxetine suggest
that venlafaxine's early efficacy on anxiety symptoms may be the basis
for its superior efficacy in depression 25.
|Results of comparative study of venlafaxine vs. fluoxetine in the treatment of depression and anxiety 12.
||20 mg per day for 12 weeks
||75 mg per day for 12 weeks
| Response rate at week 12
|Sustained response (for at least 2 weeks) at the end of the study
| Remission rate
||Venlafaxine is significantly more effective than fluoxetine in improving depressive symptoms and concomitant anxiety.
Fluoxetine (Prozac) vs. Bupropion (Wellbutrin)
Onset of action -- no difference in speed of onset of action between bupropion and fluoxetine26.
Bupropion SR and fluoxetine are similarly effective and well tolerated in the treatment of depression.
In clinical trials there were no statistically significant differences between both medications on any of the efficacy
variables 15, 16.
|Results of placebo-controlled comparison of bupropion sustained release and fluoxetine 15.
||150-400 mg per day
||20 to 60 mg per day
||Similarly effective in the treatment of depressive symptoms.
|Sexual side effects
||Fluoxetine is more frequently associated with sexual dysfunction
|Results of double-blind comparison of bupropion and fluoxetine for depression 16.
||225-450 mg per day
||20-80 mg per day
|50% or greater reduction in the HAM-D scores, number of patients, %
||37 of 61 patients, 63%
||35 of 62 patients, 58%
|Much or very much improved number of patients, %
||40 of 61 patients, 68%
||35 of 62 patients, 58%
|Prematurely discontinuation of treatment, number of patients
||16 of 61 patients, 26%
||18 of 62 patients, 29%
Premenstrual Dysphoric Disorder
Fluoxetine is significantly
superior to bupropion in the treatment of premenstrual dysphoric disorder
|Results of placebo-controlled comparison of bupropion sustained release and fluoxetine 14.
||100 mg 3 times daily
||20 mg daily
||Some improvement was noted.
||Fluoxetine was superior to bupropion. Patients satisfaction was far greater with fluoxetine.
Fluoxetine (Prozac) vs. Amitriptyline (Elavil)
Major depressive disorder
Both are effective in relieving the symptoms of depression 5.
Recent memory can be improved significantly with the fluoxetine treatment 6.
Fluoxetine and amitriptyline have comparable
efficacy in the treatment of major depression with associated anxiety 3.
Fluoxetine and amitriptyline are similarly effective treatments for fibromyalgia, and they work better in combination
than either medication alone 2.
In the study moderate or good pain relief was reported by 82% patients with amitriptyline, and by 77%
patients with fluoxetine. Fluoxetine relieved low back pain and whiplash associated cervical pain with efficacy similar to that
of amitriptyline 4.
Amitriptyline appears to be more effective than fluoxetine for migraine headache prophylaxis9.
Adverse effects are more frequent and more severe with the amitriptyline 3.
The most frequent side effects with fluoxetine are nausea, nervousness, sleep disturbances, and headaches;
and dry mouth, dizziness, and drowsiness with amitriptyline 5,
6, 8. Weight gain is associated more with
Fluoxetine (Prozac) vs. Mirtazapine (Remeron)
Major depressive disorder
Mirtazapine is significantly more
effective than fluoxetine after 3 and 4 weeks of treatment
in moderate to severe major depressive disorder 10,
Tolerability profiles are comparable except for changes in body weight.
Mirtazapine is associated with significantly more pronounced body
weight gain compared to the fluoxetine. In the study mirtazapine
was associated with a mean weight gain of 0.8 +/- 2.7 kg, whereas
fluoxetine was associated with a mean decrease in weight of 0.4 +/-
2.1 kg 10, 11.
- 1. Judge R, Parry MG, Quail D, Jacobson JG. Comparison of brief interruption of fluoxetine and paroxetine. Int Clin Psychopharmacol. 2002 Sep;17(5):217-25. PubMed
- 2. Goldenberg D, Mayskiy M, Mossey C, Ruthazer
R, Schmid C. Fluoxetine
and amitriptyline in fibromyalgia. Arthritis Rheum.
1996 Nov;39(11):1852-9. PubMed
- 3. Versiani M, Ontiveros A, Mazzotti G, Ospina
J, Da'vila J, Mata S, Pacheco A, Plewes J, Tamura R, Palacios M. Fluoxetine
versus amitriptyline in major depression with associated
anxiety. Int Clin
Psychopharmacol. 1999 Nov;14(6):321-7. PubMed
- 4. Schreiber S, Vinokur S, Shavelzon V, Pick
CG, Zahavi E, Shir Y. Fluoxetine versus amitriptyline
in musculo-skeletal pain. Isr J Psychiatry Relat Sci. 2001;38(2):88-94.
- 5. Feighner JP. A comparative trial of fluoxetine
and amitriptyline in patients with major depressive disorder. J Clin
Psychiatry. 1985 Sep;46(9):369-72. PubMed
- 6. Keegan D, Bowen RC, Blackshaw S, Saleh S,
Dayal N, Remillard F, Shrikhande S, Cebrian Perez S, Boulton A. A
comparison of fluoxetine and amitriptyline in major
depression. Int Clin Psychopharmacol. 1991 Summer;6(2):117-24. PubMed
- 7. Altamura AC, De Novellis F, Guercetti G, Invernizzi
G, Percudani M, Montgomery SA. Fluoxetine compared with amitriptyline
in elderly depression. Int J Clin Pharmacol
Res. 1989;9(6):391-6. PubMed
- 8. Young JP, Coleman A, Lader MH. A controlled
comparison of fluoxetine and amitriptyline in depressed out-patients.
Br J Psychiatry. 1987 Sep;151:337-40. PubMed
- 9. Amelin AV, Skoromets AA, Korenko LA, Tumelevich
BCh, Gonchar MA. A comparative efficiency of amitriptyline, fluoxetine
and maprotiline in prevention of migraine in attack-free period. Zh
Nevrol Psikhiatr Im S S Korsakova. 2000;100(8):20-3. PubMed
- 10. Versiani M, Moreno R, Ramakers-van Moorsel
CJ, Schutte AJ. Comparison
of mirtazapine and fluoxetine in severely depressed
patients. CNS. 2005;19(2):137-46. PubMed
- 11. Wheatley DP, van Moffaert M, Timmerman L,
Kremer CM. Mirtazapine: efficacy and tolerability in comparison with
fluoxetine in patients with moderate to severe major depressive disorder.
J Clin Psychiatry. 1998 Jun;59(6):306-12.
- 12. Patris M, Bouchard JM, Bougerol T, Charbonnier
JF, Chevalier JF, Clerc G, Cyran C, Van Amerongen P, Lemming O, Hopfner
Petersen HE. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol. 1996 Jun;11(2):129-36.
- 13. Leombruni P, Amianto F, Delsedime N, Gramaglia
C, Abbate-Daga G, Fassino S. Citalopram versus fluoxetine in bulimia nervosa: a single-blind randomized
controlled trial. Adv Ther. 2006 May-Jun;23(3):481-94. PubMed
- 14. Pearlstein TB, Stone AB, Lund SA, Scheft
H, Zlotnick C, Brown WA. Comparison of fluoxetine, bupropion, and
placebo in premenstrual dysphoric disorder. J Clin
Psychopharmacol. 1997 Aug;17(4):261-6. PubMed
- 15. Coleman CC, King BR, Bolden-Watson C, Book
MJ, Segraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A.
A placebo-controlled comparison of the effects on sexual functioning
of bupropion sustained release and fluoxetine. Clin Ther. 2001 Jul;23(7):1040-58.
- 16. Feighner JP, Gardner EA, Johnston JA, Batey
SR, Khayrallah MA, Ascher JA, Lineberry CG. Double-blind comparison
of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry.
1991 Aug;52(8):329-35. PubMed
- 17. Feiger AD, Flament MF, Boyer P, Gillespie
JA Sertraline versus fluoxetine in major depression:
a combined analysis of five double-blind comparator studies. Int Clin
Psychopharmacol. 2003 Jul;18(4):203-10. PubMed
- 18. Flament MF, Lane RM, Zhu R, Ying Z. Predictors
of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol. 1999 Sep;14(5):259-75.
- 19. Aguglia E, Casacchia M, Cassano GB, Faravelli
C, Ferrari G, Giordano P, Pancheri P, Ravizza L, Trabucchi M, Bolino
F, et al. Sertraline
versus fluoxetine in major depression. Int Clin Psychopharmacol. 1993
- 20. Bergeron R, Ravindran AV, Chaput Y, Goldner
E, Swinson R, van Ameringen MA, Austin C, Hadrava V. Sertraline and
fluoxetine in obsessive-compulsive disorder: results of
a double-blind, 6-month study. J Clin Psychopharmacol. 2002
- 21. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC,
Krebs WB. SSRI discontinuation syndrome:
a randomized clinical trial. Biol Psychiatry. 1998 Jul 15;44(2):77-87.
- 22. Geretsegger C, Bo"hmer F, Ludwig M. Paroxetine
in the elderly depressed patient: randomized comparison with fluoxetine
of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol.
1994 Spring;9(1):25-9. PubMed
- 23. Chouinard G, Saxena B, Be'langer MC, Ravindran
A, Bakish D, Beauclair L, Morris P, Vasavan Nair NP, Manchanda R,
Reesal R, Remick R, O'Neill MC. A Canadian multicenter, double-blind
study of paroxetine and fluoxetine in major depressive disorder. J
Affect Disord. 1999 Jul;54(1-2):39-48. PubMed
- 24. Silverstone PH, Ravindran A. Venlafaxine extended release compared with fluoxetine in outpatients
with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin
Psychiatry. 1999 Jan;60(1):22-8. PubMed
- 25. Rudolph RL, Feiger AD. A double-blind, randomized,
placebo-controlled trial of venlafaxine extended release and fluoxetine for the treatment of depression. J Affect Disord.
1999 Dec;56(2-3):171-81. PubMed
- 26. George MS, Lydiard RB. Speed of onset of action of the newer antidepressants--fluoxetine and bupropion. Int Clin Psychopharmacol. 1991 Winter;6(4):209-17.
- 27. Madeo B, Bettica P, Milleri S, Balestrieri A, Granata AR, Carani C, Rochira V. The effects of citalopram and fluoxetine on sexual behavior in healthy men. J Sex Med. 2008 Oct;5(10):2431-41 PubMed
- 28. De Nayer A, Geerts S, Ruelens L, Schittecatte M, De Bleeker E, Van Eeckhoutte I, Evrard JL, Linkowski P, Fossion P, Leyman S, Mignon A. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol. 2002 Jun;5(2):115-20. PubMed
Published: March 31, 2008
Last updated: July 07, 2014